RxDoctor Payments DataLook up a doctor →

Syma Iqbal, MD

Medical Oncology · Los Angeles, CANPI 1518982206

Payments from drug & device makers

$1,857,070in general payments, 2019–2025

Across 249 payments — averaging $7458.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Deciphera Pharmaceuticals Inc.$1.2M
  • E.r. Squibb & Sons, L.L.C.$243K
  • AstraZeneca$151K
  • Daiichi Sankyo Inc.$96K
  • Astellas Pharma US Inc$95K
  • Exelixis Inc.$27K
  • plus $94K from 10 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,857,070 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California

Medicare billing

Part B allowed, 2024
$68,079
Medicare patients
155
Services billed
787

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →